Board of Directors

Bruce Eaton

Bruce currently serves as the Chairman of Velocity Sciences and as the Executive Vice President and Chief Business Officer of Editas Medicine. At Editas, Bruce oversees the Company’s business development, alliance management, and strategy initiatives. Bruce has more than 30 years of experience in science, operations, business development, and corporate strategy in both public and private companies. He has a deep understanding of biotechnology and in driving innovation and development across multiple disciplines in life sciences, including diagnostics and therapeutics. He has served in C-level and director-level roles at multiple companies and acted as an advisor to numerous government and academic research institutions.

Bruce was the founding CEO of Velocity Sciences and i2 Pharmaceuticals, where both companies were formed to leverage his extensive knowledge of oligonucleotide chemistry. He joined Editas in January 2018 as part of the acquisition of assets from i2 Pharmaceuticals. Prior to i2, Bruce was Chief Operating Officer of SomaLogic, where he was responsible for operations, business development, and corporate strategy. Earlier in his career, Bruce also served as Vice President of NexaGen and was part of the team responsible for the merger with Vestar to create NexStar where he built and lead the groups responsible for GMP synthesis and analytics for the drug Macugen as well as the research and process development efforts to support the liposomal delivery technology of the drug Ambisome.

Bruce received his Ph.D. in chemistry from the University of California at Berkeley and his B.S. degrees in chemistry and biology from the University of Oregon.

Gerald Joyce

Gerald Joyce is Professor and Chief Scientific Officer at the Salk Institute in La Jolla, California. Prior to moving his laboratory to Salk in 2017, he was a Professor at Scripps Research. From 2014 to 2021 he served as Institute Director of the Genomics Institute of the Novartis Research Foundation (GNF), during which time 15 compounds were brought into human clinical trials and 3 FDA approvals were received for compounds that originated at GNF.

In his academic research, Dr. Joyce pioneered the directed evolution of nucleic acids, including the first example of the directed evolution of an RNA enzyme, the discovery of the first DNA enzyme, and the development of the first self-replicating RNA enzyme.

He received a BA from the University of Chicago in 1978 and both an MD and PhD from UCSD in 1984, then carried out postgraduate medical and research training before joining the faculty of Scripps Research in 1989.

Dr. Joyce is a member of the U.S. National Academy of Sciences, U.S. National Academy of Medicine, and Royal Swedish Academy of Sciences. He received the U.S. National Academy of Sciences Award in Molecular Biology and the U.S. National Academy of Sciences Award for Early Earth and Life Sciences.

Vic Myer, PhD

Vic Myer, Ph.D. is President and Chief Scientific Officer at Chroma Medicine and an Advisor at Atlas Venture. He also serves as an independent Board Member for Velocity Sciences, an advisor to the NIH SCGE, and an SAB member at Obsidian Therapeutics, KromaTid and Life Edit Therapeutics. Previously, he was Chief Technology Officer of Editas Medicine where he led the genome editing platform, CMC and chemistry departments.

At the Novartis Institutes for Biomedical Research, he led a technology-focused target discovery, target validation and lead finding group in the Developmental and Molecular Pathways department for 11 years. Prior to Novartis, Vic focused on industrializing and using ‘omics technologies at Millennium, Akceli and Corning.

He has B.S. from Cornell, a Ph.D. from Yale, and did his post-doc at MIT/The Whitehead.

David Brunel

Chief Executive Officer

Mr. Brunel joined Velocity Sciences in 2021 serving as its CEO and on its Board of Directors. Mr. Brunel was a co-founder, board member, and CEO of Biodesix from 2006 to 2020, a company that develops and commercializes non-invasive blood-based molecular diagnostic tests for oncology. Prior to Biodesix, Mr. Brunel was co-founder and President of SomaLogic, a company creating protein capture arrays for sensitive, high-throughput, quantitative diagnostics. He was also the founder and CEO of Unidata, Inc. which merged with Vmark Software to create Ardent Software, Inc., where he served as President and as a board member until its sale to Informix.

He served as CEO of Codestream, Ltd, acquired by Blue Phoenix Solutions, eMotion, Inc., acquired by Corbus (now part of Getty Images), and as the Chairman of Xyleme, Inc. until its sale to Bow River Capital. Additionally, Mr. Brunel is currently Chairman of the board of KromaTid, Anark Corporation, and AmideBio and on the board of HepQuant, and InOn Health.

David has a BS in Chemistry from Colorado State University and MA in International Studies from Denver University.

WE’RE innovative



We are looking for partners.

If this is something you are considering, let's talk.